GlassScriptPhysician profile
Michael J Malkowski
NPI 1932120581
$4,652.39
in general payments reported to CMS, 2019-2025
28 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,520 · 2020: $190 · 2021: $289 · 2022: $573 · 2023: $970 · 2024: $944 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,081.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $639.16 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $516.09 | 2019-2025 | |
| Ge Healthcare | $406.61 | 2019 | |
| Janssen Pharmaceuticals, INC | $399.79 | 2019-2024 | Xarelto |
| Amgen INC. | $354.64 | 2019-2025 | Repatha |
| Pfizer INC. | $302.44 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $295.87 | 2019-2024 | Lifevest |
| Sanofi-Aventis U.S. LLC | $206.20 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.30 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $185.44 | 2019-2024 | Farxiga, Andexxa |
| Kestra Medical Technology Services, INC. | $183.64 | 2022-2024 | Assure Wcd |
| Abbott Laboratories | $150.54 | 2022 | |
| Impulse Dynamics (USA) INC. | $117.57 | 2023 | Optimizer |
| Heartflow, INC. | $106.26 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $89.62 | 2021-2024 | Verquvo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $88.14 | 2021-2024 | |
| Lantheus Medical Imaging, INC. | $85.24 | 2023 | Definity |
| Abiomed | $48.83 | 2024 | Impella |
| Amarin Pharma, INC. | $46.57 | 2019-2021 | |
| Boston Scientific Corporation | $39.58 | 2019-2020 | |
| Scpharmaceuticals INC. | $38.77 | 2023 | |
| Irhythm Technologies, INC. | $30.94 | 2024 | Zio Xt Patch, Zio Monitor |
| Inspire Medical Systems, INC. | $27.62 | 2024 | Inspire |
| Xeris Pharmaceuticals, INC. | $24.44 | 2025 | Keveyis |
| Kiniksa Pharmaceuticals International, Plc | $20.31 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $18.10 | 2023 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $12.89 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Malkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.